LEADER 04569nam 2201321z- 450 001 9910557607703321 005 20231214133354.0 035 $a(CKB)5400000000045325 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77070 035 $a(EXLCZ)995400000000045325 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Metabolism/Transport and Pharmacokinetics 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (232 p.) 311 $a3-0365-2459-2 311 $a3-0365-2458-4 330 $aThis book serves to highlight the pharmacokinetics/drug?drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters. 606 $aMedicine$2bicssc 606 $aPharmaceutical industries$2bicssc 610 $atofacitinib 610 $adose-dependent pharmacokinetics 610 $ahepatic and intestinal first-pass effect 610 $arats 610 $acatalposide 610 $ain vitro human metabolism 610 $aUDP-glucuronosyltransferase 610 $asulfotransferase 610 $acarboxylesterase 610 $acelecoxib 610 $adrug?drug interaction 610 $afluorescence 610 $aHPLC 610 $ametabolism 610 $arepaglinide 610 $aHSG4112 610 $aanti-obesity agent 610 $astereoselectivity 610 $apharmacokinetics 610 $acompound K 610 $aprotopanaxadiol (PPD) 610 $abiliary excretion 610 $aintestinal metabolism 610 $aCarthamus tinctorius extract 610 $anotoginseng total saponins 610 $acomparative pharmacokinetic study 610 $alarge volume direct injection 610 $acompatibility mechanism 610 $amertansine 610 $ahuman hepatocytes 610 $acytochrome P450 610 $aUDP-glucuronosyltransferases 610 $asodium-glucose cotransporter 2 (SGLT2) inhibitors 610 $aDWP16001 610 $akidney distribution 610 $ainhibition mode 610 $adiabetes 610 $atransporter-enzyme interplay 610 $ainflux transporter 610 $aefflux transporter 610 $aphysiologically based pharmacokinetic model 610 $acytochrome P450 enzymes 610 $atiropramide 610 $ahealthy Korean subjects 610 $amodeling 610 $apopulation pharmacokinetic 610 $aquercetin 610 $abreast cancer resistance protein 610 $ainhibitor 610 $aprazosin 610 $asulfasalazine 610 $akinetic analysis 610 $afood?drug interactions 610 $aCaco-2 610 $aEpiIntestinal 610 $afirst-pass 610 $aP-gp 610 $aBCRP 610 $adrug transporter 610 $aCYP3A4 610 $aoral availability 610 $aautomatization 610 $adrug absorption 610 $adrug dosing 610 $ahead-and-neck cancer 610 $areal-time measurements 610 $ataxanes 610 $atissue engineering 610 $aUHPLC-MS/MS 610 $ametformin 610 $averapamil 610 $adrug interaction 610 $aorganic cation transporter 2 610 $arenal excretion 610 $aacute renal failure 610 $agentamicin 610 $acisplatin 610 $ahepatic CYP3A1(23) 610 $acreatinine clearance 610 $arenal clearance 610 $anonrenal clearance 615 7$aMedicine 615 7$aPharmaceutical industries 700 $aSong$b Im-Sook$4edt$01302990 702 $aSong$b Im-Sook$4oth 906 $aBOOK 912 $a9910557607703321 996 $aDrug Metabolism$93038985 997 $aUNINA